Date:11/6/2012

ainties, including those discussed in our most recent annual report filed on Form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially viable drugs; risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates; the ability of our collaborators and of Array to meet objectives tied to milestones and royalties; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks associated with our dependence on third-party service providers to successfully conduct clinical trials within and outside the United States; our ability to achieve and maintain profitability and maintain sufficient cash resources; the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities; our ability to out-license our proprietary candidates on favorable terms; and our ability to attract and retain experienced scientists and management. We are providing this information as of November 6, 2012. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such stat
'/>"/>

SOURCE Array BioPharma Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
2. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
3. PDL BioPharma Announces Third Quarter 2012 Financial Results
4. PDL BioPharma to Announce Third Quarter 2012 Financial Results on November 5, 2012
5. New Study Highlights Enabling Factors for Biopharmaceutical Innovation in Middle-Income Countries
6. SAFC Enters South Korean BioPharma Market with CrystalGenomics Agreement
7. Principia Biopharma Secures $12.5M Second Tranche In Series A Financing, Expands Senior Management Team
8. Regeneron Named Worlds #1 Biopharmaceutical Employer in Science Magazine Annual Survey
9. Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
10. PDL BioPharma Completes Regular Quarterly Dividend Payment
11. Chester County Biopharmaceutical Firm to Expand, Create 151 New Jobs